A product-specific J-code for an mUC treatment is now available

The PADCEV™ (enfortumab vedotin-ejfv) J-code is now available—J9177

Important Safety Information | Full Prescribing Information

We are sending this communication on behalf of Astellas Pharma US, Inc. and Seattle Genetics to announce the assignment of a product-specific, permanent J-code for PADCEV. The Centers for Medicare & Medicaid Services (CMS) released the July 2020 Quarterly Healthcare Common Procedural Coding System (HCPCS) File, which includes the designation of J9177 for PADCEV with the effective date of July 1, 2020.

<table>
<thead>
<tr>
<th>Trade Name</th>
<th>Strength</th>
<th>NDC</th>
<th>HCPCS Code</th>
<th>CMS Long Descriptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>PADCEV</td>
<td>20 mg</td>
<td>51144-0020-01*</td>
<td>J9177</td>
<td>Injection, enfortumab vedotin-ejfv, 0.25 mg</td>
</tr>
<tr>
<td>PADCEV</td>
<td>30 mg</td>
<td>51144-0030-01*</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Note that the product's NDC code has been "zero-filled" to ensure creation of an 11-digit code that meets HIPAA standards. The zero-fill location is indicated in bold.

Dose descriptor is provided as the smallest amount that can be billed in multiple units in order to accommodate a variety of doses.

PADCEV was approved by the U.S. Food and Drug Administration on December 18, 2019. PADCEV is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. This indication is approved under accelerated approval based on tumor response rate. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

Learn more at PADCEV.com.

Important Safety Information

Warnings and Precautions

Hyperglycemia occurred in patients treated with PADCEV, including death and diabetic ketoacidosis (DKA), in those with and without pre-existing diabetes mellitus. The incidence of Grade 3-4 hyperglycemia increased consistently in patients with higher body mass index and in patients with higher baseline A1C. In one clinical trial, 8% of patients developed Grade 3-4 hyperglycemia. Patients with baseline hemoglobin A1C ≥8% were excluded. Closely monitor blood glucose levels in patients with, or at risk for, diabetes mellitus or hyperglycemia. If blood glucose is elevated (>250 mg/dL), withhold PADCEV.

Peripheral neuropathy (PN), predominantly sensory, occurred in 49% of the 310 patients treated with PADCEV in clinical trials; 2% experienced Grade 3 reactions. In one clinical trial, peripheral neuropathy occurred in patients treated with PADCEV with or without preexisting peripheral neuropathy. The median time to onset of Grade ≥2 was 3.8 months (range: 0.6 to 9.2). Neuropathy led to treatment discontinuation in 6% of patients. At the time of their last evaluation, 19% had complete resolution, and 26% had partial improvement. Monitor patients for symptoms of new or worsening peripheral neuropathy and consider dose interruption or dose reduction of PADCEV when peripheral neuropathy occurs. Permanently
A product-specific J-code for an mUC treatment is now available

discontinue PADCEV in patients that develop Grade ≥3 peripheral neuropathy.

**Ocular disorders** occurred in 46% of the 310 patients treated with PADCEV. The majority of these events involved the cornea and included keratitis, blurred vision, limbal stem cell deficiency and other events associated with dry eyes. Dry eye symptoms occurred in 36% of patients, and blurred vision occurred in 14% of patients, during treatment with PADCEV. The median time to onset to symptomatic ocular disorder was 1.9 months (range: 0.3 to 6.2). Monitor patients for ocular disorders. Consider artificial tears for prophylaxis of dry eyes and ophthalmologic evaluation if ocular symptoms occur or do not resolve. Consider treatment with ophthalmic topical steroids, if indicated after an ophthalmic exam. Consider dose interruption or dose reduction of PADCEV for symptomatic ocular disorders.

**Skin reactions** occurred in 54% of the 310 patients treated with PADCEV in clinical trials. Twenty-six percent (26%) of patients had maculopapular rash and 30% had pruritus. Grade 3-4 skin reactions occurred in 10% of patients and included symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), bullous dermatitis, exfoliative dermatitis, and palmar-plantar erythrodysesthesia. In one clinical trial, the median time to onset of severe skin reactions was 0.8 months (range: 0.2 to 5.3). Of the patients who experienced rash, 65% had complete resolution and 22% had partial improvement. Monitor patients for skin reactions. Consider appropriate treatment, such as topical corticosteroids and antihistamines for skin reactions, as clinically indicated. For severe (Grade 3) skin reactions, withhold PADCEV until improvement or resolution and administer appropriate medical treatment. Permanently discontinue PADCEV in patients that develop Grade 4 or recurrent Grade 3 skin reactions.

**Infusion site extravasation** Skin and soft tissue reactions secondary to extravasation have been observed after administration of PADCEV. Of the 310 patients, 1.3% of patients experienced skin and soft tissue reactions. Reactions may be delayed. Erythema, swelling, increased temperature, and pain worsened until 2-7 days after extravasation and resolved within 1-4 weeks of peak. One percent (1%) of patients developed extravasation reactions with secondary cellulitis, bullae, or exfoliation. Ensure adequate venous access prior to starting PADCEV and monitor for possible extravasation during administration. If extravasation occurs, stop the infusion and monitor for adverse reactions.

**Embryo-fetal toxicity** PADCEV can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to the fetus. Advise female patients of reproductive potential to use effective contraception during PADCEV treatment and for 2 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with PADCEV and for 4 months after the last dose.

**Adverse Reactions**

Serious adverse reactions occurred in 46% of patients treated with PADCEV. The most common serious adverse reactions (≥3%) were urinary tract infection (6%), cellulitis (5%), febrile neutropenia (4%), diarrhea (4%), sepsis (3%), acute kidney injury (3%), dyspnea (3%), and rash (3%). Fatal adverse reactions occurred in 3.2% of patients, including acute respiratory failure, aspiration pneumonia, cardiac disorder, and sepsis (each 0.8%).

Adverse reactions leading to discontinuation occurred in 16% of patients; the most common adverse reaction leading to discontinuation was peripheral neuropathy (6%). Adverse reactions leading to dose interruption occurred in 64% of patients; the most common adverse reactions leading to dose interruption were peripheral neuropathy (18%), rash (9%) and fatigue (6%). Adverse reactions leading to dose reduction occurred in 34% of patients; the most common adverse reactions leading to dose reduction were peripheral neuropathy (12%), rash (6%) and fatigue (4%).

The most common adverse reactions (≥20%) were fatigue (56%), peripheral neuropathy (56%), decreased appetite (52%), rash (52%), alopecia (50%), nausea (45%), dysgeusia (42%), diarrhea (42%), dry eye (40%), pruritus (26%) and dry skin (26%). The most common Grade ≥3 adverse reactions (≥5%) were rash (13%), diarrhea (6%) and fatigue (6%).

**Lab Abnormalities**

In one clinical trial, Grade 3-4 laboratory abnormalities reported in ≥5% were: lymphocytes decreased (10%), hemoglobin decreased (10%), phosphate decreased (10%), lipase increased (9%), sodium decreased (8%), glucose increased (8%), urate increased (7%), neutrophils decreased (5%).

**Drug Interactions**

**Effects of other drugs on PADCEV** Concomitant use with a strong CYP3A4 inhibitor may increase free MMAE exposure, which may increase the incidence or severity of PADCEV toxicities. Closely monitor patients for signs of toxicity when PADCEV is given concomitantly with strong CYP3A4 inhibitors.
A product-specific J-code for an mUC treatment is now available

**Specific Populations**

**Lactation** Advise lactating women not to breastfeed during treatment with PADCEV and for at least 3 weeks after the last dose.

**Hepatic impairment** Avoid the use of PADCEV in patients with moderate or severe hepatic impairment.

Please [click here](http://editor.ne16.com/...5e672a&m=0de45b1b-f1ed-43f1-acf0-fe1b8d1a3fd4&MailID=2272830&listid=1001476&RecipientID=5253359418[7/1/2020 10:18:48 AM]) for Full Prescribing Information.

For healthcare providers in Colorado, please see our required disclosure [here](http://editor.ne16.com/...5e672a&m=0de45b1b-f1ed-43f1-acf0-fe1b8d1a3fd4&MailID=2272830&listid=1001476&RecipientID=5253359418[7/1/2020 10:18:48 AM]).

**References:**

Sincerely,

Aaron Franczek
Consultant
DK Pierce and Associates, Inc.
10910 Creek Way
Zionsville, IN 46077
(317) 873-0303
aaron.franczek@dkpierce.net

This communication is from DK Pierce & Associates and is intended to be confidential and solely for the use of the persons or entities addressed above. If you are not an intended recipient, be aware that the information contained herein may be protected from unauthorized use by privilege or law. Copy, distribution, disclosure, or other use of this information is prohibited. If you have received this communication in error, please contact the sender by return email or telephone.

© 2020 Astellas Pharma US, Inc. and Seattle Genetics, Inc. All rights reserved. 081-0079-PM 4/20
PADCEV is a trademark jointly owned by Agensys, Inc. and Seattle Genetics, Inc.
Astellas is a registered trademark of Astellas Pharma Inc.
Seattle Genetics is a registered trademark of Seattle Genetics, Inc.